Pharmacyclics LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 59
- Registration Number
- NCT03790332
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸University of California, San Francisco, California, United States
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 352
- Registration Number
- NCT03112174
- Locations
- 🇺🇸
The University of Arizona Cancer Centre-North Campus, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 193
- Registration Number
- NCT02959944
- Locations
- 🇺🇸
Arizona Oncology - Scottsdale - Cancer Transplant Institute Location /ID# 1140-1120, Scottsdale, Arizona, United States
🇺🇸LPCH Stanford /ID# 1140-1128, Palo Alto, California, United States
🇺🇸Ucsf /Id# 1140-0003, San Francisco, California, United States
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 445
- Registration Number
- NCT02947347
- Locations
- 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Sansum Clinic, Santa Barbara, California, United States
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 323
- Registration Number
- NCT02910583
- Locations
- 🇺🇸
City of Hope /ID# 1142-0047, Duarte, California, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 1142-0241, La Jolla, California, United States
🇺🇸UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 1142-0008, Orange, California, United States
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Conditions
- Metastatic Renal Cell CarcinomaAdvanced Gastric AdenocarcinomaAdvanced Urothelial CarcinomaMetastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 263
- Registration Number
- NCT02599324
- Locations
- 🇺🇸
Clearview Cancer Institute /ID# 1128-0965, Huntsville, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center /ID# 1128-0802, Gilbert, Arizona, United States
🇺🇸University of Arizona Cancer Center - Tucson /ID# 1128-1546, Tucson, Arizona, United States
informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 1504
- Registration Number
- NCT02582879
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 11
- Registration Number
- NCT02548962
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 430
- Registration Number
- NCT02436668
- Locations
- 🇺🇸
Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Arizona Center for Cancer Care, Avondale, Arizona, United States
🇺🇸St. Mary's Medical Center, Daly City, California, United States
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Breast CancerNon-Small Cell Lung CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 124
- Registration Number
- NCT02403271